Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;23(11):929-935.
doi: 10.1097/PCC.0000000000003043. Epub 2022 Jul 27.

High-Dose Midazolam for Pediatric Refractory Status Epilepticus: A Single-Center Retrospective Study

Zachary S Daniels  1 , Nina Srdanovic  2 , Karen Rychlik  1   3 , Craig Smith  1 , Joshua Goldstein  1 , Alfred L George Jr  4
Affiliations

High-Dose Midazolam for Pediatric Refractory Status Epilepticus: A Single-Center Retrospective Study

Zachary S Daniels et al. Pediatr Crit Care Med. .

Abstract

Objectives: We sought to describe the prevalence of midazolam treatment failure in children with refractory status epilepticus (RSE) and define a threshold dose associated with diminishing frequency of seizure cessation.

Design: Single center retrospective cohort study.

Setting: Single-center, quaternary-care PICU.

Patients: Children younger than 18 years old admitted to the PICU from 2009 to 2018 who had RSE requiring a continuous midazolam infusion.

Interventions: None.

Measurements and main results: We identified individuals with RSE through a data analytics inquiry. Receiver operating characteristic (ROC) curve analysis and Youden's index were used to assess the midazolam dose threshold associated with the highest sensitivity and specificity in identifying seizure cessation. A logistic regression model was used to determine if there was an association between maximum midazolam dose and seizure cessation. Of the 45 patients who met inclusion criteria for this study, 27 (60%) had seizure cessation with a midazolam infusion, whereas 18 (40%) required an additional pentobarbital infusion for seizure cessation. There was an association between maximum midazolam dose and seizure cessation, with patients more likely to fail treatment when midazolam was administered at higher doses. The maximum midazolam dose displayed high area under the ROC curve value for seizure cessation, and the Youden's J index cut-off point was 525 μg/kg/hr. Treatment above this dose was associated with diminishing frequency of seizure cessation. The median time spent titrating midazolam above 500 μg/kg/hr for those patients who required pentobarbital for seizure cessation was 3.83 hours (interquartile range, 2.28-5.58 hr).

Conclusions: In pediatric patients with RSE requiring high dose midazolam, considerable time is spent titrating doses in a range (above 500 µg/kg/hr) that is associated with diminishing frequency of seizure cessation.

PubMed Disclaimer

Conflict of interest statement

Dr. George’s institution received funding from Tevard Biosciences, Praxis Precision Medicines, and Neurocrine Biosciences; he received support for article research from the National Institutes of Health; and he received research grants from Tevard Biosciences, Praxis Precision Medicines, and Neurocrine Biosciences. The remaining authors have disclosed that they do not have any potential conflicts of interest.

References

    1. Hirsch LJ, Gaspard N, van Baalen A, et al.: Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018; 59:739–744
    1. Barzegar M, Mahdavi M, Galegolab Behbehani A, et al.: Refractory convulsive status epilepticus in children: Etiology, associated risk factors and outcome. Iran J Child Neurol. 2015; 9:24–31
    1. Chin RF, Neville BG, Peckham C, et al.; NLSTEPSS Collaborative Group: Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: Prospective population-based study. Lancet. 2006; 368:222–229
    1. Sahin M, Menache CC, Holmes GL, et al.: Outcome of severe refractory status epilepticus in children. Epilepsia. 2001; 42:1461–1467
    1. Hayashi K, Osawa M, Aihara M, et al.; Research Committee on Clinical Evidence of Medical Treatment for Status Epilepticus in Childhood: Efficacy of intravenous midazolam for status epilepticus in childhood. Pediatr Neurol. 2007; 36:366–372

LinkOut - more resources